Literature DB >> 8609897

Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.

J Kim1, Q Jiang, M Glashofer, S Yehle, J Wess, K A Jacobson.   

Abstract

The A2a adenosine receptor, a member of the G protein-coupled receptor family, is important in the regulation of dopaminergic pathways of the brain and in platelet and cardiovascular functions. In this study, the role of extracellular loops in ligand binding to the human A2a receptor was explored through site-directed mutagenesis. Four glutamate/aspartate residues (Glu151, Glu161, Glu169, and Asp170) in the second extracellular loop (E2) and a cysteine residue (Cys262) in the third extracellular loop (E3) were individually replaced with alanine and other amino acids. A proline residue (Pro173) in E2 was mutated to arginine, the homologous amino acid in A3 receptors. The binding properties of the resultant mutant receptors were determined in transfected COS-7 cells. The mutant receptors were tagged at their amino terminus with a hemagglutinin epitope, thus allowing their detection in the plasma membrane with immunological techniques. High affinity specific binding of [3H]2-[4-[(2-carboxyethyl)phenyl]ethyl-amino]-5'-N-ethylcarboxamidoad eno sine (15 nM) and [3H]8-[4-[[[[2-aminoethyl)-amino]carbonyl]methyl]oxy]phenyl]-1,3- dipropylxanthine (4nM), an A2a agonist and antagonist, respectively, was not observed with four of the mutant receptors, E151A, E151Q, E151D, and E169A, although they were well expressed at the cell surface. The E151A and E169A mutant receptors showed nearly full stimulation of adenylyl cyclase at approximately 10(3)-fold higher concentrations of 2-[4-[(2-carboxyethyl)phenyl]ethyl-amino]-5'-N-ethylcarboxamidoadenosine . The E161A mutant receptor showed as increase in affinity for the nonxanthine adenosine antagonist 9-chloro-2-(furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine(6 fold) but not for other ligands. An E169Q mutant gained affinity (5-22 fold) for adenosine derivatives (agonists) substituted at N6 but not at C2 or C5' positions. Mutant receptors D170K and P173R were similar to wild-type receptors in binding of both agonist and antagonist radioligands. A C262G mutant also resembled the wild-type receptor in radioligand binding, indicating that a potential disulfide bridge with another cysteine residue in proximity is not required for the structural integrity of the receptor. Our data suggest that certain amino acids in the second extracellular loop may be directly or indirectly involved in ligand binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609897      PMCID: PMC3425639     

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

Review 1.  Cardiovascular purinoceptors.

Authors:  R A Olsson; J D Pearson
Journal:  Physiol Rev       Date:  1990-07       Impact factor: 37.312

2.  1.7 A X-ray structure of the periplasmic ribose receptor from Escherichia coli.

Authors:  S L Mowbray; L B Cole
Journal:  J Mol Biol       Date:  1992-05-05       Impact factor: 5.469

3.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.

Authors:  S Weiss; M Sebben; J A Garcia-Sainz; J Bockaert
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

5.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.

Authors:  C D Strader; M R Candelore; W S Hill; I S Sigal; R A Dixon
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase.

Authors:  I Hide; W L Padgett; K A Jacobson; J W Daly
Journal:  Mol Pharmacol       Date:  1992-02       Impact factor: 4.436

8.  A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1983-02       Impact factor: 4.272

9.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors:  A Enjalbert; J Bockaert
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

Review 10.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

View more
  41 in total

1.  Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop.

Authors:  Heng T Duong; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2005       Impact factor: 1.381

2.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor.

Authors:  Farag F Sherbiny; Anke C Schiedel; Astrid Maass; Christa E Müller
Journal:  J Comput Aided Mol Des       Date:  2009-11       Impact factor: 3.686

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

4.  Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues.

Authors:  Veli-Pekka Jaakola; J Robert Lane; Judy Y Lin; Vsevolod Katritch; Adriaan P Ijzerman; Raymond C Stevens
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

Review 5.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

6.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

7.  Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor.

Authors:  S Moro; C Hoffmann; K A Jacobson
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

8.  Point mutations in the second extracellular loop of the histamine H2 receptor do not affect the species-selective activity of guanidine-type agonists.

Authors:  Hendrik Preuss; Prasanta Ghorai; Anja Kraus; Stefan Dove; Armin Buschauer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

9.  Ligand-dependent activation and deactivation of the human adenosine A(2A) receptor.

Authors:  Jianing Li; Amanda L Jonsson; Thijs Beuming; John C Shelley; Gregory A Voth
Journal:  J Am Chem Soc       Date:  2013-05-29       Impact factor: 15.419

Review 10.  Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Authors:  Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.